Malaria DNA vaccine - Naval Medical Research Center/Vical

Drug Profile

Malaria DNA vaccine - Naval Medical Research Center/Vical

Alternative Names: Malaria DNA vaccine VCL-2510; MuStDO 5; VCL-2510

Latest Information Update: 15 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Naval Medical Research Center
  • Class Antimalarials; DNA vaccines; Gene therapies; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-I/II for Malaria (Prevention, volunteers) in USA (IM)
  • 14 Feb 2013 Malaria DNA vaccine is still in phase I/II trials for Malaria in USA
  • 27 Apr 2010 Malaria DNA vaccine is still in phase I/II clinical development in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top